
|Videos|January 11, 2016
The Aftermath of Hepatitis C Drugs on Specialty Spending
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
3
Ribociclib Plus Fulvestrant Shows Strong PFS and OS Benefits in Patients With Invasive Lobular Carcinoma
4
FDA Approves First At-Home Treatment Device for Depression
5

















































































































































































































